Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 19/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | ATRIP | Q8WXE1 | 5/20 | 0.45 |
| ▸ | TAF1 | P21675 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | PRKDC | P78527 | 2/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492045 | 1.00 | ATR (0.46) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4194597 | 0.92 | ATR (0.54) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL2492141 | 0.90 | ATR (0.44) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4194174 | 0.90 | MTOR (0.49) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL6522294 | 0.90 | MTOR (0.49) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL2492852 | 0.90 | MTOR (0.49) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL2489878 | 0.90 | ATR (0.44) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL6518645 | 0.88 | ATR (0.52) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL2489919 | 0.88 | ATR (0.52) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4202234 | 0.88 | ATR (0.52) | ATRPIK3CAMTORKCNH2ATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102325764-A | Pyrimidine indole derivatives for the treatment of cancer | ASTRAZENECA AB | 2012-01-18 | — | — | CN | disclosed |
| EP-2379530-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ASTRAZENECA (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2010073034-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ABCG2, CYP3A7, CYP2C19 | ATR 2253/4885PIK3CA 1564/4885MTOR 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.